Use of Distal Radial Access for Recanalization of Radial Occlusions

Transradial access (TRA) is the preferred route for most percutaneous coronary procedures, with proven benefits in reducing vascular complications and shortening recovery time. However, despite its safety, it is not exempt from complications, such as radial artery occlusion (RAO). 

Although clinically silent in most cases due to collateral circulation of the wrist and hand, RAO represents a significant limitation for repeat procedures, its use in bypass grafts for surgical revascularization, or the creation of hemodialysis access.

To address this challenge, distal radial access (DRA), performed at the anatomical snuffbox, has emerged as a safe and effective alternative—not only to reduce the incidence of RAO but also to enable retrograde recanalization of previously occluded arteries.

Colletti et al. published an international multicenter study analyzing, retrospectively, a cohort of 110 patients with RAO treated across seven international centers by operators with experience exceeding 200 DRA cases. The mean age was 66 years, and 60% were male. The strategy followed a structured approach, with techniques adapted to the morphology of the distal cap (tapered or blunt), employing drilling or knuckling methods to cross the occlusion, followed by dilatation with dotterization or, in selected cases, balloon angioplasty.

Dotterization (dilation of the segment using the introducer sheath or guiding catheters) was performed in 62% of cases, while balloon angioplasty was used in the remaining 38%. Conversion to sheathless catheters was reported in 47% of patients.

Read also: Is the Acceleration Time/Ejection Time Ratio Superior to the Mean Gradient in Predicting Clinical Outcomes After TAVR?

The procedure achieved a technical success rate of 94% and a 30-day radial patency rate of 80%, with a low incidence of acute complications (4.5%: 4 radial perforations and 1 EASY III hematoma), all resolved conservatively. One of the most relevant findings of the multivariate analysis was the identification of the sheathless approach as an independent predictor of 30-day patency (OR 3.07; 95% CI: 1.10–8.59). Conversely, the use of sheaths larger than 6F (OR 0.15) and balloons over 2.25 mm (OR 0.10) was associated with lower patency rates.

Conclusions

This study reaffirms the value of DRA not only as a primary access route but also as a therapeutic tool for radial recanalization, consolidating its role within the modern interventional cardiology toolkit. The implementation of a standardized approach, with special emphasis on less invasive techniques such as sheathless use, could optimize patency outcomes and reduce the need for alternative access routes.

Original Title: Distal Radial Access for Radial Artery Recanalization Multicenter Outcomes and Stepwise Strategies to Maximize Patency.

Reference: Colletti G, Sgueglia GA, Gasparini GL, Ungureanu C, Tsigkas G, Leibundgut G, Cocoi M, Gach O, Boukhris M, Novotný V, Cocco N, Peter L, Natalis A, Novelli L, Benthakhou E, Kákonyi K, Tumscitz C, Achim A, Rusza Z. Distal Radial Access for Radial Artery Recanalization: Multicenter Outcomes and Stepwise Strategies to Maximize Patency. JACC Cardiovasc Interv. 2025 Sep 8;18(17):2140-2151. doi: 10.1016/j.jcin.2025.07.003. PMID: 40930602.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Omar Tupayachi
Dr. Omar Tupayachi
Member of the Editorial Board of solaci.org

More articles by this author

AHA 2025 | OCEAN Study: Anticoagulation vs. Antiplatelet Therapy After Successful Atrial Fibrillation Ablation

After a successful atrial fibrillation (AF) ablation, the need to maintain long-term anticoagulation (AC) remains uncertain, especially considering the very low residual embolic risk...

AHA 2025 | VESALIUS-CV: Evolocumab in High-Cardiovascular-Risk Patients Without Prior MI or Stroke

LDL cholesterol is a well-established factor for cardiovascular disease. Therapy with PCSK9 inhibitors, including evolocumab, has been shown to reduce the risk of cardiovascular...

AHA 2025 | TUXEDO-2: Post-PCI Antiplatelet Management in Diabetic Patients with Multivessel Disease — Ticagrelor or Prasugrel?

Choosing the optimal P2Y12 inhibitor for diabetic patients with multivessel coronary artery disease undergoing percutaneous coronary intervention (PCI) remains a major clinical challenge. These...

AHA 2025 | DECAF: Coffee Consumption vs. Abstinence in Patients with Atrial Fibrillation: Recurrence or Myth?

The link between coffee consumption and arrhythmia has been met with contradicting recommendations. It is widely believed that caffeine could trigger atrial fibrillation (AF)...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Impact of Baseline Systolic Blood Pressure on Blood Pressure Changes Following Renal Denervation

Renal denervation (RDN) is a guideline-recommended therapy to reduce blood pressure in patients with uncontrolled hypertension, although uncertainties remain regarding which factors best predict...

AHA 2025 | OPTIMA-AF: 1 Month vs. 12 Months of Dual Therapy (DOAC + P2Y12) After PCI in Atrial Fibrillation

Concomitant atrial fibrillation (AF) and coronary artery disease is a common occurrence in clinical practice. In these patients, current guidelines recommend 1 month of...

AHA 2025 | CLOSURE-AF: Left Atrial Appendage Occlusion (LAAO) vs. Medical Therapy in Atrial Fibrillation with High Stroke and Bleeding Risk

Atrial fibrillation (AF) is a complex condition in which patients often present with multiple comorbidities, including high bleeding risk. Percutaneous left atrial appendage occlusion...